Omixon and TBG Biotechnology Corp. (TBG), headquartered in Taiwan announce an Exclusive Distribution and Support Partnership for the Asia-Pacific region, including China, Hong Kong, Taiwan and Australia. TBG will be the exclusive distributor of Omixon’s world leading Holotype HLA product for HLA typing by NGS.
“With a common goal of driving adoption of NGS for HLA typing in the Asia-Pacific markets, TBG and their extended network of distributors is the ideal partner for the Asia-Pacific region to distribute Holotype HLA” says Dr. Peter Meintjes, Chief Commercial Officer at Omixon. Additionally, “TBG’s automated liquid handling instrument, the DX-A provides a high quality, low cost solution perfectly tailored to the market dynamics of the region”.
TBG’s Director of Sales and Marketing, Willy Hsu notes that “Omixon’s Holotype HLA has emerged as the dominant global player in HLA typing by NGS, and we are delighted to have the opportunity to bring this exciting technology to our existing customers”. TBG and Omixon have successfully optimized Holotype HLA on TBG’s DX-A Automation System and are currently completing a multi-site customer validation program to ensure reproducibility and repeatability of the liquid handling automation.
With the addition of TBG, Omixon’s distributor network covers 15 countries/territories outside of the markets in which they sell Holotype HLA directly. Nora Nagy, Market Development Manager at Omixon notes that “Our distributors have played and continue to play an important part in Omixon’s ability to spread Holotype HLA to every corner of the globe. We are delighted to be working with such a highly skilled and motivated sales and technical support partner as TBG”.
TBG is an international molecular diagnostic solutions provider and has developed a dominant presence in nearly all Asia-Pacific countries within the verticals in which they provide products. “Having established our presence in most major markets in the Asia-Pacific Region, our priority is the ongoing expansion of our product portfolio in diagnostics, specifically intending to acquire technologies that can disrupt on price and quality”, notes Willy Hsu.
Read the original article on PRWeb.